Neurology
-
The ability to predict poor outcome is important for patient care and treatment decision-making in cases of intracerebral hemorrhage (ICH). Previous studies have included relatively brief follow-up periods and small numbers of patients, and are limited in terms of considerations regarding individual brain vulnerabilities. ⋯ These findings suggest that white matter lesions, which may reflect the vulnerability of individual brains to pathologic insults, should be considered when assessing immediate, early, and long-term outcomes after intracerebral hemorrhage.
-
Editorial Comment
Aneurysmal subarachnoid hemorrhage: have outcomes really improved?
-
Randomized Controlled Trial
Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.
To determine if mexiletine is safe and effective in reducing myotonia in myotonic dystrophy type 1 (DM1). ⋯ This study provides Class I evidence that mexiletine at dosages of 150 and 200 mg 3 times daily over 7 weeks is well-tolerated and effective in reducing handgrip relaxation time in DM1.